Vaccination News Home Page

http://bmj.com/cgi/content/full/324/7348/1234/b

PDF of this article Email this article to a friend Respond to this article Read responses to this article PubMed citation Related articles in PubMed Download to Citation Manager Search Medline for articles by: Charatan, F. Alert me when: New articles cite this article

Collections under which this article appears: Other Ethics Regulation

BMJ 2002;324:1234 ( 25 May )

News

Doctor sues company over unethical marketing

Fred Charatan, Florida

Dr David Franklin, a former employee of the Warner- Lambert Pharmaceutical Company, has filed a lawsuit against the company, alleging that its sales representatives encouraged doctors to prescribe gabapentin (Neurontin) for unapproved uses.

Gabapentin was approved by the Food and Drug Administration in 1994 for the treatment of epilepsy, including elementary partial seizures and complex partial seizures with impaired consciousness.

Dr Franklin has accused Warner-Lambert's sales representatives of encouraging doctors to prescribe the drug for pain, bipolar disorder, and attention deficit disorder in children. Unsealed court documents show that some doctors, in exchange for money, allowed sales representatives into their examining rooms to meet patients, review medical charts, and recommend what drugs to prescribe.

Dr Marcia Angell, former editor of the New England Journal of Medicine, said having sales representatives tell doctors what to prescribe while examining patients was "inexcusable."

"Drug companies have no business being involved in education or clinical care," she said (New York Times, 15 May, p B2).

The documents also show that Warner-Lambert tracked whether doctors prescribed gabapentin and rewarded those who were considered high volume prescribers by paying them as speakers and consultants and also paying them to enter patients in clinical trials.

Dr Franklin estimated that Warner-Lambert's tracking programme involved 75 to 100 doctors in several northeastern states. Each doctor was paid $350 (£240; 385) or more for each day that they let sales representatives watch as they examined patients.

It is also alleged that Warner-Lambert tried to influence doctors who wrote articles about gabapentin for medical journals by paying them, sometimes secretly, and even hiring a marketing company to write first drafts.

Dr Marcia Angell said drug companies had no business being involved in education

© BMJ 2002
 

PDF of this article Email this article to a friend Respond to this article Read responses to this article PubMed citation Related articles in PubMed Download to Citation Manager Search Medline for articles by: Charatan, F. Alert me when: New articles cite this article

Collections under which this article appears: Other Ethics Regulation

Rapid Responses:

Read all Rapid Responses

off the label indication for gabapentin?

petrus tjahjadi

bmj.com, 25 May 2002 [Full text]

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.